Klaricid

Clarithromycin, the active ingredient in Klaricid, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial bronchitis, skin and soft‑tissue infections, and is used in Helicobacter pylori eradication regimens.

GNH USA supplies Klaricid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is indicated for a range of bacterial infections affecting the respiratory tract, skin and gastrointestinal system. - Community‑acquired pneumonia: eliminates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute bacterial bronchitis: relieves cough and clears bronchial pathogens. - Skin and soft‑tissue infections: treats cellulitis, erysipelas and related bacterial skin conditions. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of a multi‑drug regimen.

Adverse reactions may occur with clarithromycin therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Clostridioides difficile infection: severe colitis. - Neutropenia: marked reduction in white blood cells.

Before initiating clarithromycin, consider patient‑specific factors and monitor for adverse events. - Renal impairment: use with caution and monitor renal function. - Hepatic impairment: dose adjustment may be required; monitor liver enzymes. - Cardiac risk: avoid in patients with known QT prolongation or arrhythmias. - Concomitant medications: review for potential drug‑drug interactions. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Clarithromycin interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Cisapride: may cause serious cardiac arrhythmias. - Pimozide: increased risk of QT prolongation and ventricular arrhythmia. - Erythromycin: additive macrolide toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, increasing INR. - Theophylline: can raise serum theophylline levels, leading to toxicity. - Simvastatin: may increase risk of myopathy and rhabdomyolysis.